A Study To Evaluate Patiromer For The Management Of Hyperkalemia In Subjects Receiving Renin-Angiotensin Aldosterone System Inhibitor (RAASi) Medications For The Treatment Of Heart Failure (DIAMOND)

Overview

About this study

The purpose of this study is to determine if patiromer treatment of subjects who developed hyperkalemia while receiving RAASi medications will result in continued use of RAASi medications in accordance with heart failure (HF) treatment guidelines and thereby decrease the occurrence of the combined endpoint of cardiovascular (CV) death and CV hospitalization events compared with placebo treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age at least 18 years or greater.
  • History of symptomatic low ejection fraction heart failure (weak heart muscle).
  • Receiving any dose of a beta blocker for the treatment of HF (unless not able to tolerate).
  • Kidney function not more than mild or moderately impaired.
  • High blood potassium (> 5.0 mEq/L) currently while receiving medications for heart failure OR normal blood potassium currently but previously had high potassium in the past 12 months which caused reduction or discontinuation of heart failure medications.
  • Hospitalization for heart failure or treatment in an out- patient setting with intravenous medications within last 12 months.

Exclusion Criteria: 

  • Current acute decompensated heart failure (HF).
  • Subjects with a discharge from a hospitalization for acute decompensation of HF at least 4 weeks before Screening may be included.
  • Significant primary aortic or mitral valvular heart disease (except mitral regurgitation due to left ventricular dilatation).
  • Heart transplantation or planned heart transplantation (i.e., currently on a heart transplant list) during the study period.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Melissa Lyle, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20469374

Mayo Clinic Footer